Renée Manser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Renée Manser has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Graham Byrnes
International Agency for Research on Cancer (IARC), 69372 Lyon, France
3 shared publications Christine Stone
Department of Human Services, Victoria Prevention and National Health Priorities level 17, 120 Spencer Street Melbourne Australia 3000
2 shared publicationsDon Campbell
Monash Medical Centre Head of General Medicine, Southern Health Level 1, Block E Clayton Australia 3168
2 shared publicationsLouis B Irving
Royal Melbourne Hospital Respiratory and Sleep Medicine Grattan Street Parkville Australia 3050
2 shared publications- Michael John Abramson
School of Public Health & Preventive Medicine, Monash University Melbourne Victoria Australia
2 shared publications Anne Lethaby
University of Auckland Obstetrics and Gynaecology Private Bag 92019 Auckland New Zealand 1142
1 shared publication
Latest Publications
- Open Access
- 19 March 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (3) , CD016091
Prognosis of surgically resected clinical stage 1A non-small cell lung cancers manifesting as a subsolid nodule on computed tomography including pure ground glass nodules
Objectives This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To quantify the risk of tumour relapse/recurrence after a surgical resection of stage 1A non‐small cell lung cancer (NSCLC) as manifested on computed tomography (CT) imaging as a subsolid nodule.
- 19 March 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (3) , CD016091
Open AccessPrognosis of surgically resected clinical stage 1A non-small cell lung cancers manifesting as a subsolid nodule on computed tomography including pure ground glass nodules
Objectives This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To quantify the risk of tumour relapse/recurrence after a surgical resection of stage 1A non‐small cell lung cancer (NSCLC) as manifested on computed tomography (CT) imaging as a subsolid nodule.
- Open Access
Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer
Prevention of cancer-associated thromboembolism (TE) remains a significant clinical challenge and priority world-wide safety initiative. In this prospective non-small cell lung cancer (NSCLC) cohort, longitudinal TE risk profiling (clinical and biomarker) was undertaken to develop risk stratification models for targeted TE prevention. These were compared with published models from Khorana, CATS, PROTECHT, CONKO, and CATS/MICA. The NSCLC cohort of 129 patients, median follow-up 22.0 months (range 5.6—31.3), demonstrated a hypercoagulable profile in >75% patients and TE incidence of 19%. High TE risk patients were those receiving chemotherapy with baseline fibrinogen ≥ 4 g/L and d-dimer ≥ 0.5 mg/L; or baseline d-dimer ≥ 1.5 mg/L; or month 1 d-dimer ≥ 1.5 mg/L. The model predicted TE with 100% sensitivity and 34% specificity (c-index 0.67), with TE incidence 27% vs. 0% for high vs. low-risk. A comparison using the Khorana, PROTECHT, and CONKO methods were not discriminatory; TE incidence 17–25% vs. 14–19% for high vs. low-risk (c-index 0.51–0.59). Continuous d-dimer (CATS/MICA model) was also not predictive of TE. Independent of tumour stage, high TE risk was associated with cancer progression (HR 1.9, p = 0.01) and mortality (HR 2.2, p = 0.02). The model was tested for scalability in a prospective gastrointestinal cancer cohort with equipotency demonstrated; 80% sensitivity and 39% specificity. This proposed TE risk prediction model is simple, practical, potent and can be used in the clinic for real-time, decision-making for targeted thromboprophylaxis. Validation in a multicentre randomised interventional study is underway (ACTRN12618000811202).
Open AccessDynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer
Prevention of cancer-associated thromboembolism (TE) remains a significant clinical challenge and priority world-wide safety initiative. In this prospective non-small cell lung cancer (NSCLC) cohort, longitudinal TE risk profiling (clinical and biomarker) was undertaken to develop risk stratification models for targeted TE prevention. These were compared with published models from Khorana, CATS, PROTECHT, CONKO, and CATS/MICA. The NSCLC cohort of 129 patients, median follow-up 22.0 months (range 5.6—31.3), demonstrated a hypercoagulable profile in >75% patients and TE incidence of 19%. High TE risk patients were those receiving chemotherapy with baseline fibrinogen ≥ 4 g/L and d-dimer ≥ 0.5 mg/L; or baseline d-dimer ≥ 1.5 mg/L; or month 1 d-dimer ≥ 1.5 mg/L. The model predicted TE with 100% sensitivity and 34% specificity (c-index 0.67), with TE incidence 27% vs. 0% for high vs. low-risk. A comparison using the Khorana, PROTECHT, and CONKO methods were not discriminatory; TE incidence 17–25% vs. 14–19% for high vs. low-risk (c-index 0.51–0.59). Continuous d-dimer (CATS/MICA model) was also not predictive of TE. Independent of tumour stage, high TE risk was associated with cancer progression (HR 1.9, p = 0.01) and mortality (HR 2.2, p = 0.02). The model was tested for scalability in a prospective gastrointestinal cancer cohort with equipotency demonstrated; 80% sensitivity and 39% specificity. This proposed TE risk prediction model is simple, practical, potent and can be used in the clinic for real-time, decision-making for targeted thromboprophylaxis. Validation in a multicentre randomised interventional study is underway (ACTRN12618000811202).
- 21 June 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2013 (6) , CD001991
Screening for lung cancer
Background This is an updated version of the original review published in The Cochrane Library in 1999 and updated in 2004 and 2010. Population‐based screening for lung cancer has not been adopted in the majority of countries. However it is not clear whether sputum examinations, chest radiography or newer methods such as computed tomography (CT) are effective in reducing mortality from lung cancer. Objectives To determine whether screening for lung cancer, using regular sputum examinations, chest radiography or CT scanning of the chest, reduces lung cancer mortality. Search methods We searched electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 5), MEDLINE (1966 to 2012), PREMEDLINE and EMBASE (to 2012) and bibliographies. We handsearched the journal Lung Cancer (to 2000) and contacted experts in the field to identify published and unpublished trials. Selection criteria Controlled trials of screening for lung cancer using sputum examinations, chest radiography or chest CT. Data collection and analysis We performed an intention‐to‐screen analysis. Where there was significant statistical heterogeneity, we reported risk ratios (RRs) using the random‐effects model. For other outcomes we used the fixed‐effect model. Main results We included nine trials in the review (eight randomised controlled studies and one controlled trial) with a total of 453,965 subjects. In one large study that included both smokers and non‐smokers comparing annual chest x‐ray screening with usual care there was no reduction in lung cancer mortality (RR 0.99, 95% CI 0.91 to 1.07). In a meta‐analysis of studies comparing different frequencies of chest x‐ray screening, frequent screening with chest x‐rays was associated with an 11% relative increase in mortality from lung cancer compared with less frequent screening (RR 1.11, 95% CI 1.00 to 1.23); however several of the trials included in this meta‐analysis had potential methodological weaknesses. We observed a non‐statistically significant trend to reduced mortality from lung cancer when screening with chest x‐ray and sputum cytology was compared with chest x‐ray alone (RR 0.88, 95% CI 0.74 to 1.03). There was one large methodologically rigorous trial in high‐risk smokers and ex‐smokers (those aged 55 to 74 years with ≥ 30 pack‐years of smoking and who quit ≤ 15 years prior to entry if ex‐smokers) comparing annual low‐dose CT screening with annual chest x‐ray screening; in this study the relative risk of death from lung cancer was significantly reduced in the low‐dose CT group (RR 0.80, 95% CI 0.70 to 0.92). Authors' conclusions The current evidence does not support screening for lung cancer with chest radiography or sputum cytology. Annual low‐dose CT screening is associated with a reduction in lung cancer mortality in high‐risk smokers but further data are required on the cost effectiveness of screening and the relative harms and benefits of screening across a range of different risk groups and settings.
- 21 June 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2013 (6) , CD001991
Screening for lung cancer
Background This is an updated version of the original review published in The Cochrane Library in 1999 and updated in 2004 and 2010. Population‐based screening for lung cancer has not been adopted in the majority of countries. However it is not clear whether sputum examinations, chest radiography or newer methods such as computed tomography (CT) are effective in reducing mortality from lung cancer. Objectives To determine whether screening for lung cancer, using regular sputum examinations, chest radiography or CT scanning of the chest, reduces lung cancer mortality. Search methods We searched electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 5), MEDLINE (1966 to 2012), PREMEDLINE and EMBASE (to 2012) and bibliographies. We handsearched the journal Lung Cancer (to 2000) and contacted experts in the field to identify published and unpublished trials. Selection criteria Controlled trials of screening for lung cancer using sputum examinations, chest radiography or chest CT. Data collection and analysis We performed an intention‐to‐screen analysis. Where there was significant statistical heterogeneity, we reported risk ratios (RRs) using the random‐effects model. For other outcomes we used the fixed‐effect model. Main results We included nine trials in the review (eight randomised controlled studies and one controlled trial) with a total of 453,965 subjects. In one large study that included both smokers and non‐smokers comparing annual chest x‐ray screening with usual care there was no reduction in lung cancer mortality (RR 0.99, 95% CI 0.91 to 1.07). In a meta‐analysis of studies comparing different frequencies of chest x‐ray screening, frequent screening with chest x‐rays was associated with an 11% relative increase in mortality from lung cancer compared with less frequent screening (RR 1.11, 95% CI 1.00 to 1.23); however several of the trials included in this meta‐analysis had potential methodological weaknesses. We observed a non‐statistically significant trend to reduced mortality from lung cancer when screening with chest x‐ray and sputum cytology was compared with chest x‐ray alone (RR 0.88, 95% CI 0.74 to 1.03). There was one large methodologically rigorous trial in high‐risk smokers and ex‐smokers (those aged 55 to 74 years with ≥ 30 pack‐years of smoking and who quit ≤ 15 years prior to entry if ex‐smokers) comparing annual low‐dose CT screening with annual chest x‐ray screening; in this study the relative risk of death from lung cancer was significantly reduced in the low‐dose CT group (RR 0.80, 95% CI 0.70 to 0.92). Authors' conclusions The current evidence does not support screening for lung cancer with chest radiography or sputum cytology. Annual low‐dose CT screening is associated with a reduction in lung cancer mortality in high‐risk smokers but further data are required on the cost effectiveness of screening and the relative harms and benefits of screening across a range of different risk groups and settings.
- 24 January 2005
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (4) , CD004699
Surgery for local and locally advanced non-small cell lung cancer
Background Surgical resection (usually lobectomy) is considered the treatment of choice for many individuals with early stage non‐small cell lung cancer (NSCLC) . However much of the evidence is observational. Objectives To determine whether, in patients with early stage NSCLC, surgical resection of cancer improves disease‐specific and all‐cause mortality compared with no treatment, radiotherapy or chemotherapy. Search methods For this update we ran a new search in October 2009, using the following search strategy designed in the original review: Cochrane Central Register of Controlled Trials (CENTRAL) (accessed through The Cochrane Library, 2009, Issue 3), MEDLINE (accessed through PubMed), and EMBASE (accessed through Ovid). Selection criteria Randomised controlled trials comparing surgery alone (or in combination with other therapy) with non‐surgical therapy and randomised trials comparing different surgical approaches. Data collection and analysis A pooled hazard ratio was calculated where possible. Tests for statistical heterogeneity were performed. Main results Thirteen trials were included with a total of 2290 patients. Some of the included studies were judged as having a high risk of bias. There were no studies with an untreated control group. In a pooled analysis of three trials, overall survival was superior in patients with resectable stage I to IIIA NSCLC who underwent resection and complete mediastinal lymph node dissection compared with those undergoing resection and lymph node sampling (hazard ratio 0.63, 95% CI 0.51 to 0.78, P ≤ 0.0001) and there was no statistically significant heterogeneity. A further trial found an increased rate of local recurrence in patients with stage I NSCLC treated with limited resection compared with lobectomy. One small trial found a survival advantage in favour of chemotherapy followed by surgery compared to chemotherapy followed by radiotherapy in patients with stage IIIA NSCLC. However none of the other trials in the review demonstrated a significant improvement in overall survival in patients treated with surgery compared with non surgical therapy. Authors' conclusions Conclusions about the efficacy of surgery in NSCLC are limited by the volume and quality of the current evidence base, however lung cancer resection combined with complete mediastinal lymph node dissection is associated with a modest improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal nodes in patients with stage I to IIIA NSCLC. Current evidence suggests that in stage IIIA N2 NSCLC, chemotherapy followed by surgery is as effective as chemotherapy followed by radical radiotherapy, and radical concurrent chemotherapy and radiotherapy is as effective as induction chemoradiation followed by surgery in terms of overall survival.
- 24 January 2005
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (4) , CD004699
Surgery for local and locally advanced non-small cell lung cancer
Background Surgical resection (usually lobectomy) is considered the treatment of choice for many individuals with early stage non‐small cell lung cancer (NSCLC) . However much of the evidence is observational. Objectives To determine whether, in patients with early stage NSCLC, surgical resection of cancer improves disease‐specific and all‐cause mortality compared with no treatment, radiotherapy or chemotherapy. Search methods For this update we ran a new search in October 2009, using the following search strategy designed in the original review: Cochrane Central Register of Controlled Trials (CENTRAL) (accessed through The Cochrane Library, 2009, Issue 3), MEDLINE (accessed through PubMed), and EMBASE (accessed through Ovid). Selection criteria Randomised controlled trials comparing surgery alone (or in combination with other therapy) with non‐surgical therapy and randomised trials comparing different surgical approaches. Data collection and analysis A pooled hazard ratio was calculated where possible. Tests for statistical heterogeneity were performed. Main results Thirteen trials were included with a total of 2290 patients. Some of the included studies were judged as having a high risk of bias. There were no studies with an untreated control group. In a pooled analysis of three trials, overall survival was superior in patients with resectable stage I to IIIA NSCLC who underwent resection and complete mediastinal lymph node dissection compared with those undergoing resection and lymph node sampling (hazard ratio 0.63, 95% CI 0.51 to 0.78, P ≤ 0.0001) and there was no statistically significant heterogeneity. A further trial found an increased rate of local recurrence in patients with stage I NSCLC treated with limited resection compared with lobectomy. One small trial found a survival advantage in favour of chemotherapy followed by surgery compared to chemotherapy followed by radiotherapy in patients with stage IIIA NSCLC. However none of the other trials in the review demonstrated a significant improvement in overall survival in patients treated with surgery compared with non surgical therapy. Authors' conclusions Conclusions about the efficacy of surgery in NSCLC are limited by the volume and quality of the current evidence base, however lung cancer resection combined with complete mediastinal lymph node dissection is associated with a modest improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal nodes in patients with stage I to IIIA NSCLC. Current evidence suggests that in stage IIIA N2 NSCLC, chemotherapy followed by surgery is as effective as chemotherapy followed by radical radiotherapy, and radical concurrent chemotherapy and radiotherapy is as effective as induction chemoradiation followed by surgery in terms of overall survival.
- 26 January 2004
- Published by Wiley
- No. 1,p. CD001991
Screening for lung cancer
Background Population based screening for lung cancer has not been adopted in the majority of countries, however it is not clear whether sputum examinations, chest radiography or newer methods such as computed tomography (CT) are effective in reducing mortality from lung cancer. Objectives To determine whether screening for lung cancer, using regular sputum examinations, chest radiography or CT scanning of the chest, reduces lung cancer mortality. Search methods We searched electronic databases (the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4), MEDLINE (1966 to 2007), PREMEDLINE and EMBASE (to 2007)) and bibliographies. We handsearched the journal Lung Cancer (to 2000) and contacted experts in the field to identify published and unpublished trials. Selection criteria Controlled trials of screening for lung cancer using sputum examinations, chest radiography or chest CT. Data collection and analysis We performed an intention‐to‐screen analysis. Where there was significant statistical heterogeneity, we reported relative risks (RR) using the random‐effects model. For other outcomes we used the fixed‐effect model. Main results We included seven trials (six randomised controlled studies and one non‐randomised controlled trial) with a total of 245,610 subjects. There were no studies with an unscreened control group. Frequent screening with chest x‐rays was associated with an 11% relative increase in mortality from lung cancer compared with less frequent screening (RR 1.11, 95% CI 1.00 to 1.23). We observed a non‐statistically significant trend to reduced mortality from lung cancer when screening with chest x‐ray and sputum cytology was compared with chest x‐ray alone (RR 0.88, 95% CI 0.74 to 1.03). Several of the included studies had potential methodological weaknesses. There were no controlled studies of spiral CT. Authors' conclusions The current evidence does not support screening for lung cancer with chest radiography or sputum cytology. Frequent chest x‐ray screening might be harmful. Further methodologically rigorous trials are required.
- 26 January 2004
- Published by Wiley
- No. 1,p. CD001991
Screening for lung cancer
Background Population based screening for lung cancer has not been adopted in the majority of countries, however it is not clear whether sputum examinations, chest radiography or newer methods such as computed tomography (CT) are effective in reducing mortality from lung cancer. Objectives To determine whether screening for lung cancer, using regular sputum examinations, chest radiography or CT scanning of the chest, reduces lung cancer mortality. Search methods We searched electronic databases (the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4), MEDLINE (1966 to 2007), PREMEDLINE and EMBASE (to 2007)) and bibliographies. We handsearched the journal Lung Cancer (to 2000) and contacted experts in the field to identify published and unpublished trials. Selection criteria Controlled trials of screening for lung cancer using sputum examinations, chest radiography or chest CT. Data collection and analysis We performed an intention‐to‐screen analysis. Where there was significant statistical heterogeneity, we reported relative risks (RR) using the random‐effects model. For other outcomes we used the fixed‐effect model. Main results We included seven trials (six randomised controlled studies and one non‐randomised controlled trial) with a total of 245,610 subjects. There were no studies with an unscreened control group. Frequent screening with chest x‐rays was associated with an 11% relative increase in mortality from lung cancer compared with less frequent screening (RR 1.11, 95% CI 1.00 to 1.23). We observed a non‐statistically significant trend to reduced mortality from lung cancer when screening with chest x‐ray and sputum cytology was compared with chest x‐ray alone (RR 0.88, 95% CI 0.74 to 1.03). Several of the included studies had potential methodological weaknesses. There were no controlled studies of spiral CT. Authors' conclusions The current evidence does not support screening for lung cancer with chest radiography or sputum cytology. Frequent chest x‐ray screening might be harmful. Further methodologically rigorous trials are required.
- 22 January 2001
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (1) , CD001740
Corticosteroids for acute severe asthma in hospitalised patients
Corticosteroids are currently used routinely in the management of acute severe asthma. The optimal dose and route of administration continues to be debated. Some investigators have reported a greater benefit of higher doses of corticosteroids in the management of severe asthma, while others have not. To determine whether higher doses of systemic corticosteroids (oral, intravenous or intramuscular) are more effective than lower doses in the management of patients with acute severe asthma requiring hospital admission. Randomised controlled trials were identified from the Cochrane Airways Group Asthma Register. In addition, primary authors and content experts were contacted to identify eligible studies. Bibliographies from included studies, known reviews and texts were also searched. Studies were selected for inclusion in the review if they met the following broad inclusion criteria: described as randomised controlled trials, included patients with acute severe asthma, compared different doses of corticosteroids (any route) in 2 or more treatment arms, and had a minimum period of follow up of 24 hours. Two reviewers independently assessed the studies for inclusion and disagreement was resolved by third party adjudication. Data were extracted independently by two reviewers if the authors were unable to verify the validity of information. Missing data were obtained from authors or calculated from other data presented in the paper. The data were analysed as weighted mean differences (WMD) for primary pulmonary function outcomes using a fixed effects model. For the purposes of the review, three broad categories of corticosteroid dose (equivalent dose of methylprednisolone in 24 hours) were defined in advance: low dose (< or = 80 mg), medium dose (> 80 mg and < or = 360 mg) and high dose (> 360 mg). There were thus 3 main comparison groups: low versus medium dose, medium versus high dose and low versus high dose. Nine trials were included; a total of 344 adult patients have been studied (96 with low dose, 85 with medium dose and 163 with high dose corticosteroids). Only 6 trials provided sufficient data for the meta-analysis. There were no clinically or statistically significant differences detected in % predicted FEV1 among comparison groups after 24, 48 or 72 hours. At 48 hours, the weighted mean difference was -3.3% predicted (95% confidence interval -12.4 to + 5.8) for the low vs medium dose comparison, -1. 9% predicted (95% CI -8.1 to + 4.3) for the medium vs high dose comparison and + 0.5% predicted (95% CI - 7.8 to + 8.8) for the low vs high dose comparison. There appeared to be no significant differences in side effects or rates of respiratory failure among the varying doses of corticosteroids. No differences were identified among the different doses of corticosteroids in acute asthma requiring hospital admission. Low dose corticosteroids (< or = 80 mg/day of methylprednisolone or < or = 400 mg/day of hydrocortisone) appear to be adequate in the initial management of these adult patients. Higher doses do not appear to offer a therapeutic advantage.
- 22 January 2001
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (1) , CD001740
Corticosteroids for acute severe asthma in hospitalised patients
Corticosteroids are currently used routinely in the management of acute severe asthma. The optimal dose and route of administration continues to be debated. Some investigators have reported a greater benefit of higher doses of corticosteroids in the management of severe asthma, while others have not. To determine whether higher doses of systemic corticosteroids (oral, intravenous or intramuscular) are more effective than lower doses in the management of patients with acute severe asthma requiring hospital admission. Randomised controlled trials were identified from the Cochrane Airways Group Asthma Register. In addition, primary authors and content experts were contacted to identify eligible studies. Bibliographies from included studies, known reviews and texts were also searched. Studies were selected for inclusion in the review if they met the following broad inclusion criteria: described as randomised controlled trials, included patients with acute severe asthma, compared different doses of corticosteroids (any route) in 2 or more treatment arms, and had a minimum period of follow up of 24 hours. Two reviewers independently assessed the studies for inclusion and disagreement was resolved by third party adjudication. Data were extracted independently by two reviewers if the authors were unable to verify the validity of information. Missing data were obtained from authors or calculated from other data presented in the paper. The data were analysed as weighted mean differences (WMD) for primary pulmonary function outcomes using a fixed effects model. For the purposes of the review, three broad categories of corticosteroid dose (equivalent dose of methylprednisolone in 24 hours) were defined in advance: low dose (< or = 80 mg), medium dose (> 80 mg and < or = 360 mg) and high dose (> 360 mg). There were thus 3 main comparison groups: low versus medium dose, medium versus high dose and low versus high dose. Nine trials were included; a total of 344 adult patients have been studied (96 with low dose, 85 with medium dose and 163 with high dose corticosteroids). Only 6 trials provided sufficient data for the meta-analysis. There were no clinically or statistically significant differences detected in % predicted FEV1 among comparison groups after 24, 48 or 72 hours. At 48 hours, the weighted mean difference was -3.3% predicted (95% confidence interval -12.4 to + 5.8) for the low vs medium dose comparison, -1. 9% predicted (95% CI -8.1 to + 4.3) for the medium vs high dose comparison and + 0.5% predicted (95% CI - 7.8 to + 8.8) for the low vs high dose comparison. There appeared to be no significant differences in side effects or rates of respiratory failure among the varying doses of corticosteroids. No differences were identified among the different doses of corticosteroids in acute asthma requiring hospital admission. Low dose corticosteroids (< or = 80 mg/day of methylprednisolone or < or = 400 mg/day of hydrocortisone) appear to be adequate in the initial management of these adult patients. Higher doses do not appear to offer a therapeutic advantage.